Ferring announces changes to Executive Committee
- Lars Peter Brunse retires as Executive Vice President and Chief Production Officer
- Armin Metzger appointed Executive Vice President, Head of Global Technical Operations and Chief Production Officer, effective immediately
Saint-Prex, Switzerland – 1 July, 2019 –
Ferring Pharmaceuticals announced today that Lars Peter Brunse is retiring from his role as Executive Vice President and Chief Production Officer. Armin Metzger, previously Senior Vice President, Head of Global Pharmaceutical R&D, has been appointed Executive Vice President, Head of Global Technical Operations and Chief Production Officer, effective immediately.
“Lars Peter’s exceptional leadership has supported the strong growth of Ferring over the last 19 years, and his results continue to help people build families and live better lives,” said Per Falk, President and Chief Science Officer, Ferring Pharmaceuticals. “With Armin’s strong track record, I have no doubt that he will build on Lars’ achievements, leading our new technical operations team into the company’s next phase of growth and innovation.”
In his new role, Lars Peter will continue with responsibilities for special projects and several Board memberships within the Ferring group.
Armin joined Ferring three years ago and has had a major impact on Ferring’s Chemistry, Manufacturing and Controls (CMC) and Medical Device organisation, as well as on the R&D organisation in general. He has more than 20 years’ experience in the pharmaceutical industry and spent 17 years with Merck and Merck Serono in various global leadership positions, including as Senior Vice President, Head of Global Biologics Manufacturing and Development, where he led CMC, Medical Devices, Drug Substance and Drug Product Clinical and Commercial Manufacturing, Secondary Packaging and Medical Device Assembly. As head of this global network, he was responsible for more than 1,200 people across Europe and Canada.
The newly-formed Technical Operations organisation at Ferring will drive end-to-end global commercial manufacturing and supply, CMC, medical device and discovery technologies.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.